The US Food and Drug Administration has approved Zanvastro, marking the first time a medication has been authorized to directly treat Alexander disease. This rare and often fatal neurological disorder affects fewer than one in every million people worldwide. Prior to this approval, medical professionals could only manage symptoms without addressing the root biological causes of the condition.
Zanvastro Targets Underlying Genetic Cause
Zanvastro represents a significant shift in how doctors approach this progressive condition. Unlike previous therapies that focused solely on relieving symptoms, this new drug targets the specific genetic mutation responsible for the disease. It works by reducing the production of glial fibrillary acidic protein, or GFAP, which accumulates in brain cells and causes damage.
The drug was developed through a collaboration between Ionis Pharmaceuticals and researchers at the University of Wisconsin-Madison. The approval covers patients across all age groups, from infants to adults. Administration involves an injection into the spinal canal, delivered by a healthcare professional once every three months.
Clinical trials involving 54 patients across 13 international sites demonstrated that the treatment could stabilize motor function. Participants who received the drug for over a year showed significantly better walking speeds compared to those who did not receive the treatment. Some patients also experienced measurable improvements in their ability to move.
Three Decades of Research Lead to Breakthrough
The path to this approval began more than 30 years ago in the laboratory of Albee Messing, professor emeritus at the University of Wisconsin-Madison. Messing and his colleague Michael Brenner at the University of Alabama at Birmingham identified the genetic changes causing Alexander disease in the late 1990s. Their work revealed that mutations in the gene producing GFAP were the primary driver of the disorder.
The initial discovery came from an unexpected source. Researchers had engineered mice to produce high levels of GFAP. Instead of simply showing elevated protein levels, the mice developed abnormal protein deposits in their brains that closely resembled the lesions found in human patients. These deposits, known as Rosenthal fibers, became a defining characteristic for diagnosing the disease.
Understanding the genetic basis of the disorder allowed scientists to develop a targeted therapy. They utilized antisense oligonucleotides, a technology that uses short pieces of genetic material to interfere with the instructions cells use to make specific proteins. By lowering GFAP production, the drug aims to prevent further damage to the nervous system.
Messing emphasized the importance of the patient community in this achievement. He noted that the research program relied heavily on the support and participation of individuals living with Alexander disease and their families. Without their involvement in clinical studies, the development of this treatment would not have been possible.
Zanvastro is expected to become available in the United States in the coming weeks. For patients outside the US, access will be managed through a licensing agreement between Ionis Pharmaceuticals and Recordati, an Italian pharmaceutical company. This approval ends decades of uncertainty for families affected by the disease, offering a concrete option where none existed before.
Source: ScienceDaily
